Latest news with #ophthalmology
Yahoo
5 days ago
- Business
- Yahoo
Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative
Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative June 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company's headquarters located at Sundesk Sophia Antipolis, rue Evariste Galois, Emerald Square, Bâtiment C – 06410 agenda and the text of the draft resolutions proposed to the Ordinary and Extraordinary Shareholders' Meeting are included in the notice of meeting published in the Bulletin des Annonces Légales Obligatoires (Official Bulletin of Mandatory Legal Announcements) No. 61 dated May 21, 2025 (No. 2502198) and No. 64 dated May 28, 2025 ( No. 2501651).Appointment of an A Representative to Represent Defaulting ShareholdersIn light of the significant difficulties in reaching the required quorum, the President of the Antibes Commercial Court, has appointed by order on May 6, 2025, SCP EZAVIN-THOMAS, represented in the person of Maître Nathalie Thomas, domiciled 1, Alexandre Mari – 06000 Nice, as ad hoc representative to represent defaulting shareholders at the Ordinary and Extraordinary Shareholder's Meeting convened for June 27, 2025 on first ad hoc representative will thus represent all the shares with voting rights held by shareholders who have not participated or are not represented at this General Meeting. The participation of the ad hoc representative will thus bring the quorum to 100% of shares with voting order to ensure the neutrality of the ad hoc representative's role, the voting rights attached to the shares of the defaulting shareholders will be exercised as follows: for ordinary resolutions, whether proposed, approved or not approved by the Board of Directors: half the votes in favor and half against; for extraordinary resolutions whether proposed or approved by the Board of Directors: two-thirds in favor and one-third against; for extraordinary resolutions not approved by the Board of Directors: one-third in favor and two-thirds against; Documentation and Participation in the General MeetingThe documents relating to the General Meeting, including the text of the draft resolutions and the proxy form, are made available to shareholders at the Company's headquarters and on its website ( may vote by proxy, by internet or by attending the Ordinary and Extraordinary Shareholder Meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company's website. Shareholders may also contact the Company's Investor Relations team at ag2025nicox@ for any questions regarding the voting process. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Nicox_CP_Annonce_AGOA_Mandataire_ad_hoc_FINALSign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative
Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative June 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company's headquarters located at Sundesk Sophia Antipolis, rue Evariste Galois, Emerald Square, Bâtiment C – 06410 agenda and the text of the draft resolutions proposed to the Ordinary and Extraordinary Shareholders' Meeting are included in the notice of meeting published in the Bulletin des Annonces Légales Obligatoires (Official Bulletin of Mandatory Legal Announcements) No. 61 dated May 21, 2025 (No. 2502198) and No. 64 dated May 28, 2025 ( No. 2501651).Appointment of an A Representative to Represent Defaulting ShareholdersIn light of the significant difficulties in reaching the required quorum, the President of the Antibes Commercial Court, has appointed by order on May 6, 2025, SCP EZAVIN-THOMAS, represented in the person of Maître Nathalie Thomas, domiciled 1, Alexandre Mari – 06000 Nice, as ad hoc representative to represent defaulting shareholders at the Ordinary and Extraordinary Shareholder's Meeting convened for June 27, 2025 on first ad hoc representative will thus represent all the shares with voting rights held by shareholders who have not participated or are not represented at this General Meeting. The participation of the ad hoc representative will thus bring the quorum to 100% of shares with voting order to ensure the neutrality of the ad hoc representative's role, the voting rights attached to the shares of the defaulting shareholders will be exercised as follows: for ordinary resolutions, whether proposed, approved or not approved by the Board of Directors: half the votes in favor and half against; for extraordinary resolutions whether proposed or approved by the Board of Directors: two-thirds in favor and one-third against; for extraordinary resolutions not approved by the Board of Directors: one-third in favor and two-thirds against; Documentation and Participation in the General MeetingThe documents relating to the General Meeting, including the text of the draft resolutions and the proxy form, are made available to shareholders at the Company's headquarters and on its website ( may vote by proxy, by internet or by attending the Ordinary and Extraordinary Shareholder Meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company's website. Shareholders may also contact the Company's Investor Relations team at ag2025nicox@ for any questions regarding the voting process. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Nicox_CP_Annonce_AGOA_Mandataire_ad_hoc_FINALError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
5 days ago
- Business
- Globe and Mail
Wet Age-Related Macular Degeneration (Wet-AMD) Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight
Wet Age-Related Macular Degeneration Companies are Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. (Albany, USA) DelveInsight's ' Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Wet Age-Related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet Age-Related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration market. Key Takeaways from the Wet Age-Related Macular Degeneration Market Report In May 2025, Kodiak Sciences Inc announced results of a Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In May 2025, NexThera Co., Ltd announced results of a Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD) In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023. The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future. Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases). Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM. Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023. The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023. Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases). Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM. In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand). The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR. The leading Wet Age-Related Macular Degeneration Companies such as Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Marketed Drugs • BEOVU (Brolucizumab): Novartis BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules. • EYLEA (aflibercept): Regeneron Pharmaceuticals EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials. • VABYSMO (faricimab): Roche/ Genentech, Inc. VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels. Wet Age-Related Macular Degeneration Emerging Drugs • OPT-302: Opthea Limited OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. • KSI-501: Kodiak Sciences Inc. KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. Wet Age-Related Macular Degeneration Market Outlook Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients. The Wet Age-Related Macular Degeneration (wAMD) market is driven by several key factors, including the rising prevalence of the disease due to an aging global population, increased awareness and early diagnosis, and ongoing advancements in treatment options such as anti-VEGF therapies and emerging gene therapies. Additionally, robust research pipelines, growing healthcare expenditure, and supportive government initiatives further contribute to market growth. However, the market also faces notable barriers, such as the high cost of treatment, limited accessibility in low-income regions, the need for frequent intravitreal injections, and challenges in achieving long-term efficacy and patient adherence. Moreover, competition among therapeutic alternatives and the complex nature of drug development for retinal diseases can also hinder market expansion. Wet Age-Related Macular Degeneration Drugs Uptake The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration. Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols – BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others Scope of the Wet Age-Related Macular Degeneration Market Report Coverage- 7MM Study Period- 2020-2034 Wet Age-Related Macular Degeneration Companies- Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals Table of Content 1 Key Insights 2 Report Introduction 3 Wet AMD Market Overview at a Glance 4 Wet AMD Market: Future Perspective 5 Executive Summary 6 Key Events 7 Disease Background and Overview 8 Epidemiology and Patient Population 9 Patient Journey 10 Marketed Drugs 11 Emerging Drugs of Wet AMD 12 Wet AMD: Market Analysis 13 Key Opinion Leaders' Views 14 SWOT Analysis 15 Unmet Needs 16 Market Access and Reimbursement 17 Appendix 18 DelveInsight Capabilities 19 Disclaimer About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Bloomberg
02-06-2025
- Business
- Bloomberg
TriVista Capital CEO: Long on Santen Pharmaceutical
Masaki Gotoh, CEO and CIO at TriVista Capital, discusses his investment strategy in Japan and why he chose to go long on ophthalmology firm Santen Pharmaceutical at the Sohn Hong Kong Investment Leaders Conference. He speaks with Shery Ahn and Haidi Stroud-Watts on "Bloomberg: The Asia Trade". (Source: Bloomberg)
Yahoo
31-05-2025
- Business
- Yahoo
Ray-Ban Maker EssilorLuxottica to Buy Optegra in Medical AI Push
Ray-Ban maker EssilorLuxottica said it would buy AI-focused ophthalmology platform Optegra from MidEuropa, as part of the group's medical technology strategy. The Franco-Italian eyewear group said Friday that the deal builds on the company's offering, which spans beyond frames and lenses to include AI-powered technologies, wearables, medical instruments and science-backed eyecare solutions. It's Waymo's World. We're All Just Riding in It. Trump Says Steel and Aluminum Tariffs Will Double to 50% JPMorgan's Jamie Dimon Predicts 'Crack in the Bond Market,' Citing U.S. Fiscal Mess Taylor Swift Buys Her Early Master Recordings, Gaining Control of First Six Albums Why This Stock Market Makes So Many of Us Want to Scream Last year, EssilorLuxottica extended a partnership with Facebook parent Meta to develop smart Ray-Ban glasses, as part of its push into artificial intelligence. Optegra operates a network of over 70 eye hospitals and diagnostic facilities across the U.K., Czech Republic, Poland, Slovakia and the Netherlands. Its offering comprises ophthalmic treatments and elective vision correction procedures supported by artificial intelligence in the pre- and postoperative phases. The transaction, the financial details of which weren't disclosed, is expected to close later this year, subject to approval. Write to Andrea Figueras at The U.S. Plan to Hobble China Tech Isn't Working Judge Examines Steps to Limit Google's Reach in AI Arms Race She Always Felt Like an Outsider. Now It's This CEO's Superpower. Stocks Shrug Off Trade War to Post Best Month Since 2023 HSBC Retreats From Banking Smaller U.S. Businesses Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
